- Motley Fool
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
The biotech's shares have traded sideways for over a year, but better days could be on the near-term horizon.
- Zacks
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
CRISPR Therapeutics AG (CRSP) closed at $56.63 in the latest trading session, marking a +1.22% move from the prior day.
- InvestorPlace
The Next Big Thing After AI? 3 Sleeper Stocks to Buy Before the Boom
Chasing the next trend thing after AI is easier said than done. It is also a pretty risky strategy. Companies that have ambitious goals also need a good deal of cash to achieve growth in their areas of focus. Many such companies end up running out of capital and going bankrupt. And for those that do, investors certainly don’t want to be caught in a dilution cycle as they churn through that process. That said, it is possible to make many promising investments to try and catch the next mega trend
